Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study

The Lancet Infectious Diseases - Tập 21 - Trang 939-949 - 2021
Cristina Menni1, Kerstin Klaser2, Anna May3, Lorenzo Polidori3, Joan Capdevila3, Panayiotis Louca1, Carole H Sudre2,4, Long H Nguyen5,6, David A Drew5,6, Jordi Merino7,8,9, Christina Hu3, Somesh Selvachandran3, Michela Antonelli2, Benjamin Murray2, Liane S Canas2, Erika Molteni2, Mark S Graham2, Marc Modat2, Amit D Joshi5,6, Massimo Mangino1,10
1Department of Twin Research & Genetic Epidemiology, King’s College London, London, UK
2School of Biomedical Engineering & Imaging Sciences, King’s College London, London, UK
3ZOE Global, London, UK
4Medical Research Council Unit for Lifelong Health and Ageing, Department of Population Science and Experimental Medicine, and Centre for Medical Image Computing, Department of Computer Science, University College London, London, UK
5Clinical & Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
6Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
7Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
8Department of Medicine, Harvard Medical School, Boston, MA, USA
9Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA
10National Institute for Health Research (NIHR) Biomedical Research Centre at Guy’s and St. Thomas’ Foundation Trust, London, UK

Tài liệu tham khảo

Polack, 2020, Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine, N Engl J Med, 383, 2603, 10.1056/NEJMoa2034577 Dagan, 2021, BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting, N Engl J Med, 10.1056/NEJMoa2101765 Hunter, 2021, Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of “real-world” vaccination outcomes from Israel, medRxiv Voysey, 2021, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, Lancet, 397, 99, 10.1016/S0140-6736(20)32661-1 Ramasamy, 2021, Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial, Lancet, 396, 1979, 10.1016/S0140-6736(20)32466-1 Voysey, 2021, Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials, Lancet, 397, 881, 10.1016/S0140-6736(21)00432-3 MacKenna, 2021, Trends, regional variation, and clinical characteristics of COVID-19 vaccine recipients: a retrospective cohort study in 23·4 million patients using OpenSAFELY, medRxiv Lopez Bernal, 2021, Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England, medRxiv Vasileiou, 2021, Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study, Lancet, 10.1016/S0140-6736(21)00677-2 Hall, 2021, COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study, Lancet Menni, 2020, Real-time tracking of self-reported symptoms to predict potential COVID-19, Nat Med, 26, 1037, 10.1038/s41591-020-0916-2 Drew, 2020, Rapid implementation of mobile technology for real-time epidemiology of COVID-19, Science, 368, 1362, 10.1126/science.abc0473 Pearl, 2009 Varsavsky, 2021, Detecting COVID-19 infection hotspots in England using large-scale self-reported data from a mobile application: a prospective, observational study, Lancet Public Health, 6, e21, 10.1016/S2468-2667(20)30269-3 Murray, 2020, Accessible data curation and analytics for international-scale citizen science datasets, arXiv Saadat, 2021, Single dose vaccination in healthcare workers previously infected with SARS-CoV-2, medRxiv Krammer, 2021, Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine, medRxiv Wise, 2021, COVID-19: people who have had infection might only need one dose of mRNA vaccine, BMJ, 372, n308, 10.1136/bmj.n308 Manisty, 2021, Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals, Lancet, 397, 1057, 10.1016/S0140-6736(21)00501-8 Chodick, 2021, The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13–24 days after immunization: real-world evidence, medRxiv Baltrusaitis, 2017, Determinants of participants' follow-up and characterization of representativeness in flu near you, a participatory disease surveillance system, JMIR Public Health Surveill, 3, e18, 10.2196/publichealth.7304 Bowyer, 2020, Geo-social gradients in predicted COVID-19 prevalence in Great Britain: results from 1 960 242 users of the COVID-19 Symptoms Study app, Thorax Griffith, 2020, Collider bias undermines our understanding of COVID-19 disease risk and severity, Nat Commun, 11, 10.1038/s41467-020-19478-2
Thông tin
Thông tin xuất bản

The Lancet Infectious Diseases

Tập 21

939-949

Thông tin tác giả